Literature DB >> 11863248

Serum potassium is not associated with blood pressure tracking in the Framingham Heart Study.

Craig R Walsh1, Martin G Larson, Ramachandran S Vasan, Daniel Levy.   

Abstract

BACKGROUND: Abnormal potassium homeostasis accompanies many secondary forms of hypertension as well as uncommon inherited, monogenic forms of hypertension. We hypothesized that serum potassium may be associated with longitudinal tracking of blood pressure (BP) and development of hypertension.
METHODS: A total of 2358 participants (1292 women, 1066 men) in the Framingham Heart Study who were free of hypertension, were not taking drugs affecting potassium homeostasis, and had serum potassium measured in 1979 to 1983 were followed for longitudinal tracking of BP and development of hypertension at examination 4 years later. Progression of BP stage was defined as an increment of one or more BP category, as defined by the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI), between baseline and follow-up examinations.
RESULTS: At baseline, there were no differences in systolic or diastolic BP across serum potassium quartiles. Over 4 years of follow up, 37% (457 women, 412 men) of subjects progressed by one or more JNC-VI BP category. In a logistic regression model adjusting for multiple confounders, serum potassium quartile was not associated with risk of BP progression. During follow-up, 14% (162 women, 175 men) of subjects progressed to hypertension. After adjustment for multiple confounders, there was no significant association between serum potassium quartile and risk for progression to hypertension.
CONCLUSIONS: In our community-based study sample, serum potassium was not associated with current BP, longitudinal BP tracking, or progression to hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11863248     DOI: 10.1016/s0895-7061(01)02293-2

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic.

Authors:  Mark S Segal; Titte R Srinivas; Rajesh Mohandas; Jonathan J Shuster; Xuerong Wen; Elaine Whidden; JogiRaju Tantravahi; Richard J Johnson
Journal:  J Am Soc Hypertens       Date:  2015-05-22

2.  Association of aldosterone and cortisol with cardiovascular risk factors in prehypertension stage.

Authors:  Sadiqa Badar Syed; Masood Anwar Qureshi
Journal:  Int J Hypertens       Date:  2012-08-16       Impact factor: 2.420

3.  Associations between serum potassium and sodium levels and risk of hypertension: a community-based cohort study.

Authors:  Lu Xi; Yong-Chen Hao; Jing Liu; Wei Wang; Miao Wang; Guo-Qi Li; Yue Qi; Fan Zhao; Wu-Xiang Xie; Yan Li; Jia-Yi Sun; Jun Liu; Lan-Ping Qin; Dong Zhao
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

4.  Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials.

Authors:  Tommaso Filippini; Androniki Naska; Maria-Iosifina Kasdagli; Duarte Torres; Carla Lopes; Catarina Carvalho; Pedro Moreira; Marcella Malavolti; Nicola Orsini; Paul K Whelton; Marco Vinceti
Journal:  J Am Heart Assoc       Date:  2020-06-05       Impact factor: 5.501

5.  Anti-Hypertensive Activity of Some Selected Unani Formulations: An Evidence-Based Approach for Verification of Traditional Unani Claims Using LC-MS/MS for the Evaluation of Clinically Relevant Blood Parameters in Laboratory Rats.

Authors:  Md Adil Shaharyar; Rudranil Bhowmik; Obaid Afzal; Abdulmalik S A Altamimi; Sami I Alzarea; Waleed Hassan Almalki; Sk Zeeshan Ali; Pallab Mandal; Avishek Mandal; Mohd Ayoob; Imran Kazmi; Sanmoy Karmakar
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.